Rituximab-induced serum sickness and anaphylaxis in a child with nephrotic syndrome
TURKISH JOURNAL OF PEDIATRICS, cilt.62, sa.5, ss.884-888, 2020 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 62 Sayı: 5
- Basım Tarihi: 2020
- Doi Numarası: 10.24953/turkjped.2020.05.025
- Dergi Adı: TURKISH JOURNAL OF PEDIATRICS
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.884-888
- Anahtar Kelimeler: rituximab, nephrotic syndrome, serum sickness, anaphylaxis
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Dokuz Eylül Üniversitesi Adresli: Evet
Özet
Background. Rituximab is effective for treatment of children with refractory nephrotic syndrome (NS). However, the drug may cause serum sickness characterized by fever, rash, and arthralgia 10-14 days after primary antigen exposure or within a few days after secondary antigen exposure. Rituximab may also lead to anaphylaxis. It is important to recognize rituximab-induced serum sickness (RISS) clinically, as it may mimic various infectious or vasculitic diseases.